Transport characteristics of tramadol in the blood-brain barrier

Journal of Pharmaceutical Sciences

Volumn 103, Issue 10, 2014, Pages 3335-3341

  Kitamura, Atsushi ^a   Higuchi, Kei ^a   Okura, Takashi ^a   Deguchi, Yoshiharu ^a  

^a TEIKYO UNIVERSITY   (Japan)

Author keywords

Active transport; Blood brain barrier; Drug transport; In vitro models; Membrane transporter; Microdialysis; Organic cation transporter; Tramadol

Indexed keywords

AMMONIUM CHLORIDE; MEPYRAMINE; ORGANIC CATION TRANSPORTER 2; TRAMADOL; VERAPAMIL; NARCOTIC ANALGESIC AGENT;

ACIDIFICATION; ADULT; ANIMAL EXPERIMENT; ARTICLE; BLOOD BRAIN BARRIER; BRAIN CAPILLARY ENDOTHELIAL CELL; CELL PH; CONTROLLED STUDY; DRUG TRANSPORT; HUMAN; IN VITRO STUDY; IN VIVO STUDY; KINETICS; MALE; MEMBRANE POTENTIAL; MICRODIALYSIS; NONHUMAN; PH; RAT; ANIMAL; BRAIN; METABOLISM; TRANSFORMED CELL LINE; WISTAR RAT;

ANALGESICS, OPIOID; ANIMALS; BLOOD-BRAIN BARRIER; BRAIN; CELL LINE, TRANSFORMED; MALE; MICRODIALYSIS; RATS; RATS, WISTAR; TRAMADOL;

EID: 84923382876     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24129     Document Type: Article

References (25)

1. Raffa RB, Friderichs E, Reimann W, Shank RP, Codd EE, Vaught JL. 1992. Opioid and nonopioid components independently contribute to the mechanism of action of tramadol, an "atypical" opioid analgesic. J Pharmacol Exp Ther 260:275-285.
2. Ohtsuki S, Terasaki T. 2007. Contribution of carrier-mediated transport systems to the blood-brain barrier as a supporting and protecting interface for the brain; importance for CNS drug discovery and development. Pharm Res 24:1745-1758.
3. Okura T, Hattori A, Takano Y, Sato T, Hammarlund-Udenaes M, Terasaki T, Deguchi Y. 2008. Involvement of the pyrilamine transporter, a putative organic cation transporter, in blood-brain barrier transport of oxycodone. Drug Metab Dispos 36:2005-2013.
4. Deguchi Y, Miyakawa Y, Sakurada S, Naito Y, Morimoto K, Ohtsuki S, Hosoya K, Terasaki T. 2003. Blood-brain barrier transport of a novel micro 1-specific opioid peptide, H-Tyr-D-Arg-Phe-beta-Ala-OH (TAPA). J Neurochem 84:1154-1161.
5. Shimura T, Tabata S, Terasaki T, Deguchi Y, Tsuji A. 1992.In-vivo blood-brain barrier transport of a novel adrenocorticotropic hormone analogue, ebiratide, demonstrated by brain microdialysis and capillary depletion methods. J Pharm Pharmacol 44:583-588.
6. Sadiq MW, Borgs A, Okura T, Shimomura K, Kato S, Deguchi Y, Jansson B, Björkman S, Terasaki T, Hammarlund-Udenaes M. 2011. Diphenhydramine active uptake at the blood-brain barrier and its interaction with oxycodone in vitro and in vivo. J Pharm Sci 100:3912-3923.
7. + /OC) antiporter in human brain capillary endothelial cell line hCMEC/D3, a human blood-brain barrier model. Fluids Barriers CNS 26:10:8.
8. Cisternino S, Chapy H, André P, Smirnova M, Debray M, Scherrmann JM. 2013. Coexistence of passive and proton antiporter-mediated processes in nicotine transport at the mouse blood-brain barrier. AAPS J 15:299-307.
9. Tega Y, Akanuma S, Kubo Y, Terasaki T, Hosoya K. 2013. Blood-to-brain influx transport of nicotine at the rat blood-brain barrier: Involvement of a pyrilamine-sensitive organic cation transport process. Neurochem Int 62:173-181.
10. + antiporter that interacts with addictive drugs. J Cereb Blood Flow Metab 29:1293-1304.
11. Azodi-Deilami Saman, Abdoussa Majid, Seyedi Rezvaneh S. 2010.Synthesis and characterization of molecularly imprinted polymer for controlled release of tramadol. Cent Eur J Chem 8:687-695.
12. Fridén M,Winiwarter S, Jerndal G, Bengtsson O,Wan H, Bredberg U, Hammarlund-Udenaes M, Antonsson M. 2009. Structure-brain exposure relationships in rat and human using a novel data set of unbound drug concentrations in brain interstitial and cerebrospinal fluids. J Med Chem 52:6233-6243.
13. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, Tricoire-Leignel H, Nicotra A, Bourdoulous S, Turowski P, Male DK, Roux F, Greenwood J, Romero IA, Couraud PO. 2005. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. FASEB J 19:1872-1874.
14. Shawahna R, Uchida Y, Decleves X, Ohtsuki S, Yousif S, Dauchy S, Jacob A, Chassoux F, Daumas-Duport C, Couraud PO, Terasaki T, Scherrmann JM. 2011. Transcriptomic and quantitative proteomic analysis of transporters and drug metabolizing enzymes in freshly isolated human brain microvessels. Mol Pharm 8:1332-1341.
15. Löscher W, Potschka H. 2005. Blood-brain barrier active efflux transporters: ATP-binding cassette gene family. NeuroRx 2:86-98.
16. Carl SM, Lindley DJ, Das D, Couraud PO, Weksler BB, Romero I, Mowery SA, Knipp GT. 2010. ABC and SLC transporter expressionand pot substrate characterization across the human CMEC/D3 blood-brain barrier cell line. Mol Pharm 7:1057-1068.
17. 3, and metabolic inhibitors. J Gen Physiol 67:91-112.
18. Thomas RC. 1984. Experimental displacement of intracellular pH and the mechanism of its subsequent recovery. J Physiol 354:3-22.
19. Okura T, Kato S, Takano Y, Sato T, Yamashita A, Morimoto R, Ohtsuki S, Terasaki T, Deguchi Y. 2011. Functional characterization of rat plasma membrane monoamine transporter in the blood-brain and blood-cerebrospinal fluid barriers. J Pharm Sci 100:3924-3938.
20. Deguchi Y, Terasaki T, Kawasaki S, Tsuji A. 1991. Muscle microdialysis as a model study to relate the drug concentration in tissue interstitial fluid and dialysate. J Pharmacobiodyn 14:483-492.
21. Terasaki T, Deguchi Y, Kasama Y, Pardridge WM, Ysuji A. 1992.Determination of in vivo steady-state unbound drug concentration in the brain interstitial fluid by microdialysis. Int J Pharm 81:143-152.
22. Grond S, Sablotzki A. 2004. Clinical pharmacology of tramadol. Clin Pharmacokinet 43:879-923.
23. Szabo Z, Ravert HT, Gozukara I, Geckle W, Seki C, Sostre S, Peller P, Monsein L,Natarajan TK, Links JM,Wong DF, Dannals RF,Wagner HN Jr. 1993. Noncompartmental and compartmental modeling of the kinetics of carbon-11 labeled pyrilamine in the human brain. Synapse 15:263-275.
24. Gillen C, Haurand M, Kobelt DJ, Wnendt S. 2000. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol 362:116-121.
25. Bostrom E, Hammarlund-Udenaes M, Simonsson USH. 2008.Blood-brain barrier transport helps to explain discrepancies in in vivo potency between oxycodone and morphine. Anesthesiology 108:495-505.